Pharmacokinetic interactions and adverse drug experiences in rheumatoid arthritis-Reference-Cited by-同舟云学术

Pharmacokinetic interactions and adverse drug experiences in rheumatoid arthritis

Published:1991-03 Issue:1 Volume:1 Page:69-77
ISSN:0925-4692
Container-title:Inflammopharmacology
language:en
Short-container-title:Inflammopharmacology

Author:

Furst D. E.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Immunology

Link

http://link.springer.com/content/pdf/10.1007/BF02735463.pdf

Reference45 articles.

1. Harris ED Jr. The clinical features of rheumatoid arthritis. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of Rheumatology, 3rd edition. Philadelphia: W B Saunders; 1989: 943–974.

2. Zvaifler NJ. Etiology and pathogenesis of rheumatoid arthritis. In: McCarty DJ, ed. Arthritis and Allied Conditions, 11th edition. Philadelphia: Lea Febiger, 1989:659–673.

3. Erickson N, Furst DE. Mechanism of action of NSAID. Am Assoc Clin Chem. 1988;9:9–18.

4. Abramson S, Edelson H, Kaplan H, Ludewig R, Weissman G. Inhibition of neutrophil activation by NSAID. Am J Med. 1984;77(suppl 4B):3–6.

5. Day RO, Furst DE, Dromgoole SH, Kamm B, Roe R, Paulus HE. Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clin Pharmacol Ther. 1982;31:733–740.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics;Pharmacogenetics;2001-04

2. Comparing the strengths and weaknesses of observational and experimental studies using a postmarketing surveillance study as a protypic example;Seminars in Arthritis and Rheumatism;1993-10

3. Effects of human recombinant IL-1β on established experimental arthritis in rats;Inflammopharmacology;1992-09